Sanandan Ojha


Pluvicto Approval Launches Theranostics in Prostate Cancer

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

Danielle Hammond, MD


Combination of Venetoclax and Hypomethylating Agents Show Efficacy in AML

Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.

Niyati Nathwani, MD


Post–COVID-19 Infection Remains a Concern in Patients With Cancer

Many questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.

Jashodeep Datta, MD


Investigating KRAS/TP53 Co-Alterations in Pancreatic Cancer

Jashodeep Datta, MD, explains KRAS and TP53 co-alterations in patients with pancreatic cancer.

Sajeve S. Thomas, MD


Optimizing the Management of Melanoma: Future Directions in Care

Closing out his discussion on the management of metastatic melanoma, expert oncologist Sajeve Thomas, MD, summarizes unmet needs and looks toward future evolutions in the treatment paradigm.

Terence Friedlander, MD


The Future of Neoadjuvant Immunotherapy in MIBC

Dr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.

Amir Mortazavi, MD


Experts Compare Available Regimens for a Patient With Sarcomatoid Features

During a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.

Erin Crane, MD, MPH


Adapting to Second-Line Restrictions of Niraparib in Ovarian Cancer

The approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.

Joel Neal, MD, PhD


Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLC

The panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.

Ben Derman, MD


Higher MRD Threshold Could Guide Discontinuation of Myeloma Maintenance

Ben Derman, MD, discussed results from a trial investigating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.

Jillian E. Thompson, NP, Georgetown University Lombardi Comprehensive Cancer Center


NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKI

Expert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.

Suzanne Morris, DVM, MWC


Biomarkers in Renal Cell Carcinoma: Present Utility and Future Possibility

Wenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.

Jackie Collins


ENDOLA Study Demonstrates Promise of Olaparib Triplet in Endometrial Cancer

An olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.

Gizelka A. David-West, MD


Ovarian Cancer Awareness Month: Strides in Up-front and Maintenance Therapy

Gizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.

Gayathri Ravi, MD


Utilizing MRD Testing in the Myeloma Space

Gayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.

Arun Azad, MBBS, PhD


Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate Cancer

Arun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.

Chris Ryan


First-Line Osimertinib Displays Comparable Survival Outcomes Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC

New results from the phase 2 APPLE trial shows how the use of osimertinib in the upfront setting compares with combination therapy in patients with EGFR-positive non–small cell lung cancer.

Brett Simon, MD, PhD


Remote Monitoring Improves Management of Symptoms in Patients With Lung Cancer After Surgery

Brett Simon, MD, PhD, discusses an ongoing program at his institution that aims to improve symptoms and outcomes for patients with lung cancer who have undergone surgery.

Jason Porter, MD


Key Takeaways Regarding Biomarker Testing for mNSCLC

Closing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.

Bijal Shah, MD, MS


Future Directions and Unmet Needs in T-ALL

Bijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.

Eleni Efstathiou, MD


PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.

Seth Wander, MD, PhD


Excitement Shown With CDK4/6 Inhibitors and More in Breast Cancer Research

Seth Wander, MD, PhD, discusses what research and topics excite him when looking to further evaluate future treatments for patients with breast cancer.

Clayton Lau, MD


Pandemic Leads to Delays in Crucial Early Cancer Screening Tests

Clayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.